

Agenda 29 May 2018, AstraZeneca Gothenburg

Time	Programme
08:30	Optional - Site Tour Amazing Journey
09:30	Registration and networking
	Welcome and opening remarks
10:00	<i>Marcus Bjäreland, Project Lead, AstraZeneca Exchange 2018</i> <i>Jan-Olof Jacke, CEO, AstraZeneca Sverige AB</i>
10:10	Life Science in Sweden - Opportunities and Challenges <i>Jenni Nordborg, Director Life Sciences, Government Offices of Sweden</i>
10:30	Mixing business models and linking logics in a 4D life science reality <i>Magnus Björsne, CEO, AstraZeneca BioVentureHub</i> <i>Matti Ahlqvist, Site Director, AstraZeneca Gothenburg</i>
10:45	Coffee break
	What is a new treatment worth?
11:30	<i>Suzanne Håkansson, Senior Director, Government Affairs for Europe & Nordic Baltic AstraZeneca</i> <i>Gustaf Befrits, Stockholm läns landsting</i> <i>Anders Blanck, Läkemedelsindustriföreningen</i> <i>Penilla Gunther, MP, Christian Democratic Party, Swedish Parliament</i>
12:45	Lunch
13:15	Digital Therapeutics - The next frontier in precision medicine <i>Matthew Bonam, Global Project Leader, Intelligent Pharmaceuticals</i> <i>Representative from Boston Consulting Group</i>
14:00	Drugging the undruggable - Harnessing new modalities in drug discovery and development <i>Eric Valeur, Associate Director, Medicinal Chemistry AstraZeneca</i> <i>Anders Holmén, Vice President and Head of Pharmaceutical Sciences</i> <i>Kevin Lee, CEO, Bicycle Therapeutics</i>
14:45	Introduction to CoValley <i>Anna Maria Fuxén, CEO, CoValley</i> <i>Marcus Bjäreland, Project Leader, AstraZeneca Exchange 2018</i> <i>Matti Ahlqvist, Site Director, AstraZeneca Gothenburg</i>
15:00	Break and walk to nearby CoValley building
15:30	Welcome to CoValley <i>Anna Maria Fuxén, CEO, CoValley</i>
15:35	Collaboration for success <i>Michael Treschow, Chairman of the Wallenberg Foundation Investment Committee</i> <i>Jacob Lund, Director of External Communications, AstraZeneca Sweden</i>
16:10	Digital transformation: a key success factor <i>Johan Lindén, CEO, Gaia System AB</i> <i>Cecilia Sandqvist, CSO, Gaia System AB</i>
16:25	Business Development - Partnerships for the Future <i>Ian Kirk, Vice President, Business Development Operations AstraZeneca</i>
16:35	Summary and introduction to the afternoon activities <i>Marcus Bjäreland, Project Lead, AstraZeneca Exchange 2018</i> <i>Anna Maria Fuxén, CEO, CoValley</i>
16:40	Mingle with the speakers from today Senior Leaders from AstraZeneca, The CoValley Board, AstraZeneca Business Developers, AstraZeneca BioVentureHub, CoValley Designers and Architects, Research Funding Organisations, Venture Cap representatives, and more to be confirmed.
17:00	Dinner and networking
19:00	Event ends

Key Speakers



Jenni Nordborg

Jenni Nordborg, PhD, is National Coordinator and Director of Life Sciences at the Government Offices of Sweden, heading the newly installed Office for Life Sciences. She is also Director and Head of the Health Division at VINNOVA, the Swedish Governmental Innovation Agency.

Skills and Experience

Dr. Nordborg is active in strategic innovation policy development and implementation within health and life science on national and international level. Her network includes international innovation policy, entrepreneurship and in the health and life science ecosystem. Dr. Nordborg has experience from senior management positions in both the private and public sector and she works actively in the cross-section between life science and IT.

Other Appointments

Board member of the Linnaeus University. Dr. Nordborg has a research background from Chalmers University of Technology and has worked at several international high-level research facilities such as the Tokyo University facility in Tsukuba, Japan, Brookhaven National Labs in the US, and University of Western Australia.



Michael Treschow

Michael Treschow is the Chairman of the Investment Committee, Wallenberg Foundation AB, Chairman of the Research Institute of Industrial Economics, Board member of Knut and Alice Wallenberg Foundation and Member of the Royal Academy of Engineering Science.

Skills and Experience

Previously he has also been Chairman of the board of Unilever between 2007-2016, Chairman of the board of Ericsson between 2002-2011 as well as Chairman of the board of Electrolux from 2004 to 2007. Before joining Electrolux in 1997 as Chief Executive Officer, he was the President and Chief Executive Officer of Atlas Copco. Michael has previously held non-executive roles with Investor AB, Atlas Copco AB, SKF AB, ABB, Saab AB, Parker-Hannifin Corp and as chairman of Dometic Group. During 2004 and 2007 Michael Treschow was the Chairman of the Swedish Confederation of Enterprise. He holds a Master of Science from the Institute of Technology, Lund, Sweden.



Eric Valeur

Eric Valeur is passionate about disruptive science and currently leads New Modalities Medicinal Chemistry within Cardiovascular and Metabolic Diseases in the IMED Biotech Unit at AstraZeneca.

Skills and Experience

Derived from about 15 years drug discovery experience gained at Merck, Novartis and AstraZeneca, his vision is to integrate chemical spaces to move away from the typical silos of the pharma industry, in essence leveraging the potential of each therapeutic modality either separately or as hybrids. He is also eager to build bridges between business and science to establish a climate for innovation, where risk taking, collaboration with academia and biotechs, and entrepreneurship are continuously embraced. Eric holds a PhD in Organic chemistry from the University of Edinburgh, U.K. and an MBA from Imperial College London, U.K.



Matthew Bonam

Matthew Bonam is the head of AstraZeneca's Intelligent Pharmaceuticals group in PT&D. Intelligent Pharmaceuticals deliver digital therapeutics; combinations of connected drug delivery devices, medical sensors, clinical and behavioural algorithms and medical device software which optimise clinical outcomes when used with AstraZeneca medications.

Skills and Experience

Matthew developed the initial business case for Intel Pharma in 2013, and since that point has led the development of AstraZeneca's digital therapeutics strategy. Matt is very active externally to AstraZeneca, supporting various IMI, EFPIA and other consortia in the area of digital health. Matt also acts as an advisor to a number of SME's developing digital health tools.



Suzanne Håkansson

Senior Director, Government Affairs for Europe & Nordic Baltic AstraZeneca

Skills and Experience

Suzanne leads government affairs activities for NOBA and act as a senior expert in government relations for Sweden and European Oncology areas.

During the last four years Suzanne has been VP Healthcare Affairs for AstraZeneca NoBa, in charge of market access, government affairs and communication. Prior to joining AstraZeneca in 2010 she worked in the Swedish Government offices with innovation and growth strategies and was the Director of Policy Intelligence at the Swedish government's Institute for Growth Policy Studies, managing the international science attaché activities. She has also been a management consultant working with analysis and leadership development in the public sector.



Anna-Maria Fuxén

CEO, CoValley

Skills and Experience

Today, Anna Maria is appointed CEO of Vectura and Next Step's joint venture company CoValley Gothenburg. She is responsible for creating a living place where Life-Science and Industry meet to develop future innovations and services for better physical and mental health conditions.

Her solid experience from complex projects within the real estate world is an asset to carry out the CoValley-project to become a dynamic World-class research arena that promotes new collaborations, drive innovative working methods and solutions and achieve business missions. To meet the challenges of the future, Anna Maria is "the team leader that will" create an environment full of venues, where both small and large companies can exchange the real breakthrough ideas.

Additional speakers



Matti Ahlqvist
Site Director,
AstraZeneca Gothenburg



Gustaf Befrits
Health Economist,
Stockholm County Council



Marcus Bjäreland
Project Leader,
AstraZeneca Exchange 2018



Magnus Björnsne
CEO,
AstraZeneca BioVentureHub



Anders Blanck
Director General,
LIF



Penilla Gunther
MP
Christian Democratic Party,
Swedish Parliament



Anders Holmén
Vice President and Head of
Pharmaceutical Sciences



Jan-Olof Jacke
CEO,
AstraZeneca Sweden AB



Ian Kirk
Vice President, Sweden Business
Development Operations



Kevin Lee
CEO,
Bicycle Therapeutics



Johan Lindén
CEO,
Gaia System AB



Jacob Lund
Director of External Communications,
AstraZeneca AB



Cecilia Sandqvist
CSO,
Gaia System AB